Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 6, 2010
Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice
Rafke Schoffelen, Winette T A van der Graaf, Gerben Franssen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 22, 2004
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates
Gary L Griffiths, Chien-Hsing Chang, William J McBride, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2012
Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer
Rafke Schoffelen, Winette T A van der Graaf, Robert M Sharkey, et al.
Clinical Lymphoma
|
July 3, 2003
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
Donald E Tsai, Ivan Maillard, Stephen J Schuster, et al.
EJNMMI Physics
|
October 27, 2015
Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy
Wietske Woliner-van der Weg, Rafke Schoffelen, Robert F Hobbs, et al.
Frontiers in Medicine
|
December 8, 2015
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients
Caroline Bodet-Milin, Ludovic Ferrer, Aurore Rauscher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial
Françoise Kraeber-Bodéré, Alain Faivre-Chauvet, Ludovic Ferrer, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 20, 2014
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer
Rafke Schoffelen, Wietske Woliner-van der Weg, Eric P Visser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2015
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N Starodub, Allyson J Ocean, Manish A Shah, et al.
Molecular Cancer Therapeutics
|
April 1, 2010
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts
Rafke Schoffelen, Robert M Sharkey, David M Goldenberg, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 6, 2010
Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice
Rafke Schoffelen, Winette T A van der Graaf, Gerben Franssen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 22, 2004
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates
Gary L Griffiths, Chien-Hsing Chang, William J McBride, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2012
Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer
Rafke Schoffelen, Winette T A van der Graaf, Robert M Sharkey, et al.
Clinical Lymphoma
|
July 3, 2003
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
Donald E Tsai, Ivan Maillard, Stephen J Schuster, et al.
EJNMMI Physics
|
October 27, 2015
Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy
Wietske Woliner-van der Weg, Rafke Schoffelen, Robert F Hobbs, et al.
Frontiers in Medicine
|
December 8, 2015
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients
Caroline Bodet-Milin, Ludovic Ferrer, Aurore Rauscher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial
Françoise Kraeber-Bodéré, Alain Faivre-Chauvet, Ludovic Ferrer, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 20, 2014
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer
Rafke Schoffelen, Wietske Woliner-van der Weg, Eric P Visser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2015
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N Starodub, Allyson J Ocean, Manish A Shah, et al.
Molecular Cancer Therapeutics
|
April 1, 2010
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts
Rafke Schoffelen, Robert M Sharkey, David M Goldenberg, et al.
Page
of 12